Study Details
Study of Intermittent OSI-906 Dosing
This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).
Clinicaltrials.gov ID
The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
Astellas Study ID
The unique identification code given by the study sponsor.
OSI-906-102
EudraCT ID
The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).
2006-005938-20
Condition
Advanced/Metastatic Cancer
Phase
These clinical trials are usually the first time an experimental treatment is studied in a small group of people.
Phase 1
Age
18 years - N/A
Sex
Female & Male
Product
N/A
Type
A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
Interventional
Trial Dates
Jul 2007 - Sep 2010
Masking
None (Open Label)
Enrollment number
79
A Phase I Dose Escalation Study of Intermittent Oral OSI-906 dosing in Patients with Advanced Solid Tumors
Study summary
Study documents
Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Study of Intermittent OSI-906 Dosing? Contact us by filling our your information to the right and we’ll respond to you.
Locations
MD Anderson Cancer Center
Houston, United States, 77030
Drug Development Unit, Royal Marsden Hospital
Sutton, United Kingdom, SM2 5PT